Open access
Open access
Powered by Google Translator Translator

Post Hoc Secondary Analysis of RCT: Rivaroxaban monotherapy is associated with better outcomes vs. combination therapy with antiplatelets in patients with atrial fibrillation and stable coronary artery disease.

17 Jun, 2022 | 11:07h | UTC

Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial – JAMA Cardiology (free for a limited period)

Commentaries:

Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease: Does Less Mean More? – JAMA Cardiology (free for a limited period)

Rivaroxaban Mono vs. Combo Therapy for Thrombotic and Bleeding Events in AF – American College of Cardiology

Rivaroxaban Monotherapy Linked to Lower Event Risk in Patients with AF, Stable CAD – HCPLive

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.